Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 7/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976944 | 1.00 | CNR2 (0.44) | CNR2TTKPTK2CNR1NPY5R | |
| SCHEMBL3259857 | 1.00 | CNR2 (0.44) | CNR2TTKPTK2CNR1NPY5R | |
| SCHEMBL4765090 | 0.86 | TTK (0.46) | TTKCRHR1PDGFRACCNE1CDK2 | |
| SCHEMBL4974279 | 0.85 | NQO2 (0.41) | CNR2TTKCNR1CRHR1PDGFRA | |
| SCHEMBL4766022 | 0.84 | TTK (0.52) | TTKPTK2MERTKAXLGAA | |
| SCHEMBL4766150 | 0.83 | TTK (0.54) | TTKPTK2MERTKAXLGAA | |
| SCHEMBL4766125 | 0.82 | TTK (0.51) | TTKPTK2LRRK2GAA | |
| SCHEMBL2954902 | 0.77 | TTK (0.45) | TTKPTK2LRRK2MERTKAXL | |
| SCHEMBL4766351 | 0.77 | TTK (0.45) | TTKPTK2LRRK2MERTKAXL | |
| SCHEMBL4766346 | 0.77 | GAA (0.43) | TTKPTK2LRRK2MERTKZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | claimed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | CNR2 1449/4885TTK 4589/4885PTK2 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.